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Abstract
As the number of obese people is globally increasing, reports about the putative protective effect of obesity in life-threatening
diseases, such as subarachnoid hemorrhage (SAH), are gaining more interest. This theory—the obesity paradox—is challenging to
study, and the impact of obesity has remained unclear in survival of several critical illnesses, including SAH. Thus, we performed a
systematic review to clarify the relation of obesity and SAH mortality. Our study protocol included systematic literature search in
PubMed, Scopus, and Cochrane library databases, whereas risk-of-bias estimation and quality of each selected study were eval-
uated by the Critical Appraisal Skills Program and Cochrane Collaboration guidelines. A directional power analysis was performed
to estimate sufficient sample size for significant results. From 176 reviewed studies, six fulfilled our eligibility criteria for qualitative
analysis. One study found paradoxical effect (odds ratio, OR = 0.83 (0.74–0.92)) between morbid obesity (body mass index (BMI)
> 40) and in-hospital SAHmortality, and another study found the effect between continuously increasing BMI and both short-term
(OR = 0.90 (0.82–0.99)) and long-term SAH mortalities (OR = 0.92 (0.85–0.98)). However, according to our quality assessment,
methodological shortcomings expose all reviewed studies to a high-risk-of-bias. Even though two studies suggest that obesity may
protect SAH patients from death in the acute phase, all reviewed studies suffered frommethodological shortcomings that have been
typical in the research field of obesity paradox. Therefore, no definite conclusions could be drawn.
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Introduction
Subarachnoid hemorrhage (SAH) is characterized as an
acute cerebrovascular disease with multiple systemic
complications and long intensive care unit (ICU) period
[43]. Since roughly one-fourth [24] of SAH patients die
suddenly before reaching a hospital ward and another
one-fourth within the first 30 days [25], factors affecting
the acute phase mortality are of interest.
Obesity is a well-known risk factor for increased morbidity
and mortality in the general population [13, 14]. As the num-
ber of obese persons is globally increasing [10], a theory
called the obesity paradox has aroused increasing interest in
recent years. According to this theory, overweight and obese
people may have a survival benefit in various acute illnesses
and medical conditions. In stroke subtypes other than SAH,
such as intracerebral hemorrhage (ICH) [7, 21] and ischemic
stroke [20, 22, 35, 45, 47], being overweight or obese is asso-
ciated with a favorable outcome. However, the true impact of
BMI on the survival of any ICU patient group has remained
unclear, and several studies have reported controversial results
about the effects of obesity on the outcome of critically ill
patients [1, 16, 31]. Since contributing comorbidities and a
critical illness itself are presumably strong predictors of out-
come, one of the major challenges in many previous obesity
paradox studies has been the heterogeneity in the etiology of
critical illnesses leading to ICU admission. Since only a few
critical but relatively common acute illnesses among working-
age and relatively healthy people invariably lead to long and
expensive ICU periods that are further burdenedwith systemic
complications, determining the role of obesity in survival has
thus remained overly challenging.
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SAH, which affects working-age and relatively healthy
people, is an optimal acute and critical illness to study the
effect of obesity on short-term mortality. Contrary to other
stroke subtypes, namely ICH and ischemic stroke [29], neither
systematic reviews nor meta-analyses have been conducted on
the topic of SAH survival and obesity. Therefore, our purpose
was to review the previous literature on the possible effect of
obesity on SAH survival. Because some studies have sug-
gested that the obesity paradox can be explained by selection
bias, confounding factors and inappropriate study designs [4,
9, 12, 19, 41, 42], we also tried to evaluate the quality of
previous studies. Our hypothesis was that the obesity paradox
is true (i.e., obesity (metabolic reservoir capacity) protects
critically ill patients from death), and that this protective effect
can be investigated by studying SAH patients, who often have
lengthy and potentially catabolic ICU stays.
Materials and methods
Study protocol is available in the international prospective
register of systematic reviews (PROSPERO, code
CRD42018100003) and follows the checklist of Preferred
Reporting Items for Systematic review and Meta-Analyses
(PRISMA) [39] (Online Resource 1).
Search strategy
Details of the literature search strategy are described in Online
Resource 2. Briefly, the search was based on both keywords and
index terms and utilized three different databases: PubMed,
Scopus, and Cochrane library. A study question and eligibility
criteria were formulated using the four-step PICO (Patients,
Intervention, Controls, Outcome) principle [17]. Case reports,
case series, letters, commentaries, book chapters, animal studies,
and descriptive studies without calculated risk estimates (hazard
ratio (HR), odds ratio (OR) or relative risk (RR)) were excluded.
Quality of studies
To evaluate the heterogeneity and research methods of previ-
ous studies, we chose to use the Cochrane Collaboration
Handbook and Critical Appraisal Skills Program (CASP)
[15]. Based on the appropriate checklists, we focused on se-
lection, detection, and measurement bias; limited and residual
confounding; as well as on statistical power and causality
between exposures and outcomes. To specify the sources of
bias, we created six typical domains to describe these limita-
tions wherein each domain had specific requirements classi-
fying the studies into low, unclear or high-risk-of-bias catego-
ries (Online Resource 2). Finally, reviewed studies were
grouped into either low-quality or high-quality categories.
To reach the high-quality category, all six domains had to be
categorized as low-risk-of-bias.
Statistical analyses
A directional power analysis was performed to estimate suffi-
cient sample size for significant results. The protective effects of
being overweight, obese, and morbidly obese were optimistical-
ly estimated using an OR of 0.8 for BMI 25–29.9, OR = 0.7 for
BMI 30–39.9, and OR = 0.6 for BMI ≥ 40, with a reference 30-
day mortality figure for the normal weight category (BMI =
18.5–24.9) approximated to 25% for hospital-based studies
and 40% for studies that also included sudden-death SAHs be-
fore hospitalization [25]. Standard values were used for signif-
icance (p < 0.05) and statistical power (p = 0.8). Additionally,
depending on the amount of high-quality studies, I2 statistics for
heterogeneity and random effects models for calculation of
pooled estimates were prepared for possible meta-analysis.
Results
The literature search is depicted in Fig. 1. The search yielded
175 articles, and 1 article [36] was found through reference list
screening of the 175 articles. Of the 176 publications, 5 [8, 11,
18, 36, 46] fulfilled the eligibility criteria. Additionally, one
study [27] outside of our literature search fulfilled the criteria
and thus was added to further qualitative analysis. All 177
articles were published in English.
Study characteristics varied considerably (Table 1). Three
studies [27, 36, 46] recruited cohorts and measured BMI
values years before SAHs, whereas three [8, 11, 18] were
based on hospital admission registers with BMI values mea-
sured upon admission.
Study 1 In a Norwegian study, Sandvei et al. [36] prospective-
ly examined incidence, case fatality, and preictal risk factors
for survival among 214 (59% male; mean age 47 years) SAH
patients, including also sudden-death SAHs before hospitali-
zation. Mean pre-SAH follow-up was 16 years, with post-
SAH follow-up divided into short-term (3 and 30 days) and
long-term (6 months). BMI was measured years before SAH
at enrollment and categorized according to WHO guidelines.
No re-measurements of BMI were performed at admission.
Study 2 Yamada et al. [46] studied risk factors for fatal SAHs
in a Japanese population-based prospective study. BMI calcu-
lations were based on self-administered questionnaires at en-
rollment, and BMI values were divided into low (BMI <
18.5), medium (BMI 18.5–24.9), and high (BMI ≥ 25) cate-
gories. During the follow-up of 1,086,963 person-years and a
median follow-up time of 9.9 years, 244 (36%male; mean age
63 years) SAH deaths were reported. Mortality was verified
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from the national cause of death register. No post-SAH fol-
low-up was performed, and no re-measurements of BMI were
performed on admission.
Study 3 In the third pre-SAH follow-up study, Lindbohm et al.
[27] investigated risk factor differences between sudden-death
and hospitalized SAH patients in a large prospective cohort
study from Finland. During the follow-up of 1.52 million
person-years and a median follow-up time of 23 years, 98 of
543 SAH patients (46%male; mean age 61 years) died outside
of hospital wards. BMI was measured years before SAH and
analyzed only as a continuous variable. Neither hospital
follow-up nor re-measurement of BMI was performed.
Study 4 Using the hospital-based register of the Nationwide
Inpatient Sample (NIS) in the USA, Dasenbrock et al. [8]
evaluated the association of both obesity (BMI 30–40) and
morbid obesity (BMI > 40) with various outcomes after
SAH. BMI categories were indirectly estimated by using reg-
istered ICD-9-CM diagnosis codes of obesity and morbid
obesity, whereas controls consisted of NIS patients without
either diagnosis. Between 2002 and 2011, 18,281 (31% male;
mean age 54 years) SAH patients were included in the analy-
ses of in-hospital mortality.
Study 5 In another study based on the NIS, Elliott et al. [11]
determined the impact of morbid obesity (BMI ≥ 40) on
non-traumatic SAH outcomes. In-hospital mortality anal-
yses were based on 224,561 (40% male; mean age 59
years) SAH patients diagnosed between years 2008 and
2013. BMI categories were also indirectly estimated by
using registered ICD-9-CM codes of morbid obesity.
NIS patients with BMI < 40 values served as a control
group.
Study 6 In the third study from the USA, Hughes et al. [18]
examined the association of obesity with both short-term
(in-hospital or within 30 days after hospital discharge)
and long-term (> 24 months) outcomes. BMI was mea-
sured at hospital admission and analyzed as a
Fig. 1 Flow chart of the literature
search
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continuous variable in univariate and multivariate anal-
yses. The hospital-based study included 305 (35% male;
mean age 56 years) SAH patients admitted between
2002 and 2011.
Risk-of-bias and quality of studies Based on the Cochrane
Collaborator Handbook and CASP checklist, the select-
ed domains for risk-of-bias estimation were the follow-
ing: inclusion of sudden-death SAHs, valid obesity mea-
surements, proper obesity analysis, control for confounding,
comprehensive short-term follow-up, and sufficient sample
size (Online Resource 2). None of the studies fulfilled the
criteria for low risk-of-bias classification in all six domains;
thus, all six studies [8, 11, 18, 27, 36, 46] were classified in the
low-quality category (Table 2).
Power analysis Based on the pre-defined effect estimations
and power analysis, we calculated that in studies with
sudden-death SAHs (reference mortality 40%), the minimum
cohort size for significant results was 1128 SAH patients (564
per category) when comparing overweight (BMI 25–30) and
normal weight (BMI 18.5–24.9) patients (estimated OR =
0.8), 488 (244 per category) when comparing obese (BMI >
30) and normal weight patients (estimated OR = 0.7) and 266
(133 per category) when comparing morbidly obese (BMI >
40) and normal weight patients (estimated OR = 0.6).
Additionally, in hospital-based studies (reference mortality
25%), the minimum cohort sizes were 1094, 466, and 250,
respectively. Based on these criteria, only two [8, 11] of the six
studies consisted of an adequate sample size to reach sufficient
statistical power (Table 2).
Table 1 Study characteristics
First author Country Year SAH cases Mean age Sex (% male) Follow-up time Obesity categories
Cohort studies with preictal follow-up


















Cohort studies from hospital-based registers
Dasenbrock USA 2017 18,281 54.2 31.3 In hospital NO (BMI < 30)
Obese (BMI = 30–40)
MO (BMI > 40)
Elliot USA 2017 224,561 59.4 40.2 In hospital NMO (BMI ≤ 40)
MO (BMI > 40)
Hughes USA 2015 305 55.8 35.2 Short-term (in hospital or





NR not reported, MO morbidly obese patients, NMO nonmorbidly obese patients, NO nonobese patients
*Mean follow-up time
Table 2 Risk of bias evaluation. Plus sign (+) represents low-risk, NA (not applicable) unknown risk, and minus sign (−) high-risk-of-bias
First author Sudden-death SAHs Obesity measurement Obesity analysis Short-term follow-up Confounding control Sufficient sample size
Low-quality studies
Sandvei + − + + − −
Yamada NA − − NA + −
Lindbohm + − − − + −
Dasenbrock − − − + − +
Elliot − − − + − +
Hughes − + − + − −
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Short-termmortality The definition of “short term” varied
between studies (Table 1). Only the Norwegian study
[36] included sudden-death SAHs before hospitalization
in their short-term (30-day) follow-up. However, con-
trary to Lindbohm et al. [27], no separate association
analyses for outside hospital deaths were performed.
Three [8, 11, 18] studies, all conducted in the USA,
started the follow-up from hospital admission. All these
studies assessed in-hospital mortality rates and associa-
tions, but one study also included deaths until 30 days
post-discharge.
Two studies [11, 18] found an association between BMI
values and short-term SAH mortality (Table 3). First, Elliot
et al. [11] found an inverse association (obesity paradox) be-
tween morbid obesity (BMI > 40) and SAH-related in-hospital
mortality (OR=0.83) in a multivariate model (Table 3).
Second, Hughes et al. [18], with a somewhat longer
follow-up of up to 30 days post-discharge, also found an in-
verse association (obesity paradox) between SAH mortality
and increasing BMI values (Table 3) in both univariate (OR
= 0.91) and multivariate (OR = 0.90) models. The study
reached statistical significance despite our power analysis
Table 3 SAH studies reporting associations between BMI and mortality






Univariate analysis Multivariate analysis
Short-term mortality
Sandvei 3 days – Underweight (< 18.5) – –
Normal weight (18.5–24.9) – Reference
Overweight (25–29.9) – 0.6 (0.3–1.4)
Obese (≥ 30) – 1.1 (0.4–3.1)
30 days – Underweight (< 18.5) – –
Normal weight (18.5–24.9) – Reference
Overweight (25–29.9) – 1.1 (0.6–2.0)
Obese (≥ 30) – 0.9 (0.3–2.1)
Dasenbrock In hospital – Non–obese (< 30) Reference Reference
Obese (30–40) 0.84 (0.65–1.09) 0.90 (0.69–1.18)
Morbidly obese (> 40) 0.75 (0.54–1.06) 0.77 (0.54–1.11)
Elliot In hospital – Nonmorbidly obese (≤ 40) – Reference
Morbidly obese (> 40) – 0.83 (0.74–0.92)
Hughes In hospital or 30 days after first discharge – Continuously 0.91 (0.84–0.98) 0.90 (0.82–0.99)
Long-term mortality
Sandvei 6 months Underweight (< 18.5) – 1.6 (0.1–28.4)
Normal weight (18.5–24.9) – Reference
Overweight (25–29.9) – 1.0 (0.5–1.9)
Obese (≥ 30) – 1.0 (0.4–2.4)
Hughes > 24 months – Continuously 0.92 (0.86–0.97) 0.92 (0.85–0.98)
No reported follow-up
Yamada NR Both Low (< 18.5) 1.63 (1.06–2.50) 1.82 (0.98–3.38)
Moderate (≥ 18.5 and < 25.0) Reference Reference
High (≥ 25.0) 1.02 (0.73–1.43) –
Men Low (< 18.5) 1.85 (0.91–3.75) 2.72 (1.03–7.23)
Moderate (≥ 18.5 and < 25.0) Reference Reference
High (≥ 25.0) 0.73 (0.38–1.38) –
Women Low (< 18.5) 1.52 (0.89–2.60) 1.44 (0.64–3.21)
Moderate (≥ 18.5 and < 25.0) Reference Reference
High (≥ 25.0) 1.16 (0.79–1.73) –
Lindbohm Before hospitalization – Continuously – 0.86 (0.68–1.09)
BMI body mass index, CI confidence interval, HR hazard ratio, NR not reported, OR odds ratio
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suggested that the cohort size was inadequate to reach signif-
icance. Two other studies [8, 36] concluded that no significant
associations existed between BMI and short-term SAH mor-
tality. The last two studies [27, 46] did not define the time
frame of short-term follow-up.
Long-term mortality In addition to short-term mortality, two
studies also analyzed long-term mortality (Table 3). Only
Hughes et al. [18] found an inverse association (obesity para-
dox) between continuously increasing BMI values and long-
term (> 24 months) post-SAH mortality in both univariate
(OR = 0.92) and multivariate (OR = 0.92) models (Table 3).
Mortality without a defined time frame of follow-up Two
studies [27, 46] did not define a follow-up time for hospitalized
patients. First, Yamada et al. [46] found an association between
underweight (BMI < 18.5) patients and fatal SAHs in general
(Table 3). In a univariate analysis, the association was reported
for both sexes (HR = 1.63), whereas in the multivariate analy-
sis, low BMI remained an independent risk factor only for men
(HR = 2.73) (Table 3). The study found no significant associa-
tions between overweight/obesity (BMI ≥ 25) and mortality
when using normal weight patients as a reference group
(Table 3). Second, Lindbohm et al. [27] reported an inverse
association between increasing BMI and all SAH cases (HR
= 0.90). However, when analyses were done separately for
suddenly died and hospitalized SAH patients, no significance
was reached. Additionally, in comparison analysis, no BMI
difference was found between sudden-death and hospitalized
SAH patients (p = 0.81 for men, p = 0.76 for women).
Meta-analysis Due to methodological differences and the ab-
sence of high-quality studies, a quantitative meta-analysis was
impractical to conduct.
Discussion
Two studies [11, 18] found an obesity paradox in SAH mor-
tality, but methodological shortcomings relegate these studies
into a high-risk-of-bias category; therefore, firm conclusions
about a protective effect of obesity in SAHmortality cannot be
drawn. Although the reported obesity paradox can be ex-
plained at least partly by methodological shortcomings, phys-
iological mechanisms explaining better survival of obese pa-
tients are also possible. For example, protective mechanisms
might relate to an increased metabolic reserve of adipose or
muscle mass, which could improve tolerance of major cata-
bolic and inflammatory events among critically ill patients
treated in ICUs. Supporting this theory, a few studies [3, 8,
34] have related obesity to more favorable outcomes, mea-
sured using the modified Rankin Scale (mRS), and milder
overweight to lower complication rates as well. On the other
hand, other studies have reported contradictory findings [33,
37, 44].
While a protective effect of obesity in SAH survival is still
questionable, morbidly obese SAH patients in particular seem to
have several disadvantages. In SAH, postoperative infections
[8], venous thromboembolisms [8, 26, 38], acute respiratory
failure [11], fever [32], prolonged hospitalization [11], and
non-routine discharge [8] are associated with higher BMI.
Since obese patients tend to have higher complication rates
and longer hospital stays, studies on SAH outcome may have
a performance bias relating to differing short-term treatments. In
addition to higher complication rates, morbid obesity increases
hospital costs in SAH [11]. However, if the obesity paradox is
true, the higher treatment costs and longer hospitalizations of
obese or morbidly obese patients could be better justified.
In other stroke subtypes, sudden deaths before hospitaliza-
tion are less common than in SAH [5, 40]. In SAH, nearly half
of 1-year deaths occur before hospitalization and around 90%
within the first 30 days [25]. Since hospitalized SAH patients
often stay 2–3 weeks in the ICU and the majority of deaths
occur within the first month following the ictus, a follow-up
time of 30 days seems optimal in assessing any effects of obe-
sity on mortality in SAH.Moreover, since less than 5% of SAH
patients die between 30 days and 1 year [25], SAH appears to
be a rather optimal acute disease to examine any effects of
obesity on the short-term survival of critically ill patients.
Limitations in previous studies
Four studies [8, 11, 18, 46] excluded sudden-death SAHs.
Studies missing roughly 25% of all SAHs and about 50% of
fatal cases have a theoretical risk for selection bias. Even
though one previous study did not find BMI differences be-
tween sudden-death and hospitalized SAH patients [27], no
comparison was made between fatal cases only. Since the
same study found that sudden-death SAH patients have sig-
nificantly worse overall risk factor profiles than the hospital-
ized patients [27], even a minimal BMI difference between
sudden SAH deaths and hospitalized fatal SAHs may distort
hospital-based registers to the extent of losing study reliability.
In the Norwegian study with both sudden and hospitalized
SAH deaths in the analyses [36], no comparisons between
the groups were made.
With regard to obesity assessments, all six studies had sev-
eral shortcomings. First, three studies [27, 36, 46] measured
BMI only at enrollment. Since most adults gain weight until
serious illnesses late in life or until the onset of sarcopenia
[28], those who were overweight at enrollment are likely to
also be overweight or obese at the onset of SAH. Therefore,
the use of premorbid BMI is likely underestimating the effect
of obesity. To avoid false negative results, future studies with
long preictal monitoring periods could perform BMI
remeasurements at admission. Second, two studies analyzed
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obesity as a continuous variable [18, 27], while three used
only combined BMI categories, such as non-obese (BMI <
30) [8], non-morbidly obese (BMI < 40) [11], or high BMI
(BMI > 25) [46] categories. Therefore, statistical analyses of
weight extremes could not be conducted. Since the effect of
obesity is unlikely linear (i.e., the fatter the better) and differ-
ences by obese severity have also been reported in SAH mor-
tality, the comparison between overweight (BMI 25–29.9),
obese (BMI 30–39.9), and morbidly obese (BMI ≥ 40) SAH
patients is difficult to conduct if, for example, all patients with
BMI values over 25 are combined into one category. Third,
two studies estimated BMIs by relying on physician reports
[8, 11], and one study used self-administered questionnaires
[46] without controlling for measurement bias. All studies
used only BMI as an obesity variable. Since BMI sensitivity
has been reported to be only 50% for high mass of body fat
[30], future studies could also consider other obesity variables
with better sensitivity such as waist and hip circumference
measurements, magnetic resonance imaging (MRI), dual-
energy X-ray absorptiometry (DEXA), or bio-impedance of
body.
Only two studies, NIS register-based studies [8, 11] from
the USA, fulfilled the criteria of sufficient sample size provid-
ing high statistical power for analyses. Any protective effect of
high BMI values is likely smaller than our optimistic estima-
tion, so the other four studies [18, 27, 36, 46] likely had in-
sufficient power to achieve significant results. In addition, our
directional analysis did not consider effects of potential con-
founding, thus further underestimating the required cohort
sizes.
Confounders in studies on the obesity paradox in SAH
In a recent large prospective follow-up study, Lindbohm et al.
[27] found that the risk for sudden SAH death seems to be
highest among people with the worst risk factor profile (i.e.,
among heavy smokers and people with high blood pressure
values). Both smoking [6] and high blood pressure values [14]
have been associated with obesity. In terms of smoking, a
large study of nearly 300,000 participants [19] reported that
the observed obesity paradox in patients with cardiovascular
diseases vanished after analyzing only non-smokers. For these
reasons, we presumed that both smoking and blood pressure
should be treated as confounders in low-risk-of-bias studies of
the obesity paradox in SAH. Overall, two studies [27, 46]
fulfilled this criterion (Tables 2 and 3).
As potential other confounders, obese patients often suffer
from metabolic syndrome, diabetes, coronary artery disease,
and peripheral vascular disease. Although these comorbidities
might also impact the survival of critically ill patients, no
high-quality evidence exists, suggesting an association be-
tween these comorbidities and short-term SAH mortality.
Moreover, as the prevalence of these comorbidities is low in
SAH patients [2, 23], we did not consider these factors as
likely confounders, and therefore, they were not regarded
mandatory in statistical analyses to reach the classification of
low-risk-of-bias. In contrast, other factors, such as SAH se-
verity and rebleeding, have been associated with higher mor-
tality rates; no evidence relates these findings to obesity
groups. Furthermore, Rinaldo et al. [34] found an effect of
BMI on SAH outcome, and this effect varied depending on
the treatment modality (clipping versus coiling). However, the
study found no differences after using the validated WHO
categories for BMI. In addition, the characteristics between
treatment groups varied significantly. Since convincing evi-
dence of treatment confounding in SAH does not exist, we
did not include this factor in bias classifications. In brief, fu-
ture studies about obesity paradox in SAH should try to con-
sider at least smoking and hypertension as potential con-
founders and perhaps evaluate if composite variables of car-
diovascular risk modify the relation of BMI and SAH
mortality.
Although the literature search was done systematically uti-
lizing three different databases, we may have missed some
relevant publications. For example, large studies with compre-
hensive and wide-ranging risk factor assessments may have
neglected minor and especially negative findings in their
indexing. This type of reporting and indexing bias may cause
the exclusion of studies like the one by Lindbohm et al. [27].
Furthermore, we used only English search terms, assuming
that clinically relevant studies have been conducted in large
hospitals and subsequently reported in English. Lastly, we
were not able to conduct a meta-analysis due to methodolog-
ical differences and the absence of high-quality studies.
Conclusions
None of the reviewed obesity paradox studies were
confirmative, and effects of obesity on the risk of death among
critically ill SAH patients remain to be studied in more detail.
However, since the poor-quality evidence suggests that the
obesity paradox may exist in SAH and since the number of
obese patients is globally increasing, future studies on the
topic are encouraged. To avoid major biases, future studies
should perhaps try to include sudden-death SAHs in their
analyses, use valid and timely obesity measurements on all
SAH patients, and aim for reasonable cohort sizes.
Acknowledgements We would like to thank information specialist Tiina
Heino for consultation and additional advice on the search protocol and
Alyce Whipp for language revision.
Funding information Open access funding provided by University of
Helsinki including Helsinki University Hospital. IR received research
grants from the Finnish Medical Foundation, Juho Vainio Foundation,
Maire Taponen Foundation, and Petri Honkanen Foundation.
1561Neurosurg Rev (2020) 43:1555–1563
Compliance with ethical standards Study protocol is avail-
able in the international prospective register of systematic reviews
(PROSPERO, code CRD42018100003) and follows the checklist of
Preferred Reporting Items for Systematic review and Meta-Analyses
(PRISMA).
Disclaimer Reported foundations have no personal or institutional fi-
nancial interests concerning this study.
Conflict of interest The authors declare that they have no conflict of
interest.
Ethical approval This article does not contain any studies with human
participants or animals performed by any of the authors.
Informed consent The review was based on systematic literature search
and thus, included no personal data.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. Abhyankar S, Leishear K, Callaghan FM, Demner-Fushman D,
McDonald CJ (2012) Lower short- and long-term mortality associ-
ated with overweight and obesity in a large cohort study of adult
intensive care unit patients. Crit Care 16:R235. https://doi.org/10.
1186/cc11903
2. Adams HP Jr, Putman SF, Kassell NF, Torner JC (1984) Prevalence
of diabetes mellitus among patients with subarachnoid hemorrhage.
Arch Neurol 41:1033–1035. https://doi.org/10.1001/archneur.
1984.04050210031009
3. Badjatia N, Monahan A, Carpenter A, Zimmerman J, Schmidt JM,
Claassen J, Connolly ES, Mayer SA, Karmally W, Seres D (2015)
Inflammation, negative nitrogen balance, and outcome after aneu-
rysmal subarachnoid hemorrhage. Neurology 84:680–687. https://
doi.org/10.1212/WNL.0000000000001259
4. Banack HR, Kaufman JS (2013) The “obesity paradox” explained.
Epidemiology 24:461–462. https://doi.org/10.1097/EDE.
0b013e31828c776c
5. Black M, Graham DI (2002) Sudden unexplained death in adults
caused by intracranial pathology. J Clin Pathol 55:44–50
6. Carreras-Torres R, Johansson M, Haycock PC, Relton CL, Davey
Smith G, Brennan P, Martin RM (2018) Role of obesity in smoking
behaviour: Mendelian randomisation study in UK Biobank. BMJ
361:k1767. https://doi.org/10.1136/bmj.k1767
7. Dangayach NS, Grewal HS, De Marchis GM, Sefcik RK, Bruce R,
Chhatlani A, Connolly ES, Falo MC, Agarwal S, Claassen J,
Schmidt JM, Mayer SA (2018) Does the obesity paradox predict
functional outcome in intracerebral hemorrhage? J Neurosurg 129:
1125–1129. https://doi.org/10.3171/2017.5.JNS163266
8. Dasenbrock HH, Nguyen MO, Frerichs KU, Guttieres D, Gormley
WB, Ali Aziz-Sultan M, Du R (2017) The impact of body habitus
on outcomes after aneurysmal subarachnoid hemorrhage: a
Nationwide Inpatient Sample analysis. J Neurosurg 127:36–46.
https://doi.org/10.3171/2016.4.JNS152562
9. Dehlendorff C, Andersen KK, Olsen TS (2014) Body mass index
and death by stroke: no obesity paradox. JAMA Neurology 71:
978–984. https://doi.org/10.1001/jamaneurol.2014.1017
10. Eckel RH, York DA, Rossner S, Hubbard V, Caterson I, St Jeor ST,
Hayman LL, Mullis RM, Blair SN, American Heart A (2004)
Prevention Conference VII: obesity, a worldwide epidemic related
to heart disease and stroke: executive summary. Circulation 110:
2968–2975. https://doi.org/10.1161/01.CIR.0000140086.88453.
9A
11. Elliott RS, Godoy DA, Michalek JE, Behrouz R, Elsehety MA,
Hafeez S, Rios D, Seifi A (2017) The effect of morbid obesity on
subarachnoid hemorrhage prognosis in the United States. World
Neurosurg 105:732–736. https://doi.org/10.1016/j.wneu.2017.06.
068
12. Ferreira I, Stehouwer CD (2012) Obesity paradox or inappropriate
study designs? Time for life-course epidemiology. J Hypertens 30:
2271–2275. https://doi.org/10.1097/HJH.0b013e32835b4fe0
13. Flegal KM, Kit BK, Orpana H, Graubard BI (2013) Association of
all-cause mortality with overweight and obesity using standard
bodymass index categories: a systematic review and meta-analysis.
JAMA 309:71–82. https://doi.org/10.1001/jama.2012.113905
14. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis
AH (2009) The incidence of co-morbidities related to obesity and
overweight: a systematic review and meta-analysis. BMC Public
Health 9:88. https://doi.org/10.1186/1471-2458-9-88
15. Harrison JK, Reid J, Quinn TJ, Shenkin SD (2017) Using quality
assessment tools to critically appraise ageing research: a guide for
clinicians. Age Ageing 46:359–365. https://doi.org/10.1093/
ageing/afw223
16. Hogue CW Jr, Stearns JD, Colantuoni E, Robinson KA, Stierer T,
Mitter N, Pronovost PJ, Needham DM (2009) The impact of obe-
sity on outcomes after critical illness: a meta-analysis. Intensive
Care Med 35:1152–1170. https://doi.org/10.1007/s00134-009-
1424-5
17. Huang X, Lin J, Demner-Fushman D (2006) Evaluation of PICO as
a knowledge representation for clinical questions. AMIA Annu
Symp Proc 2006:359–363
18. Hughes JD, SamarageM, Burrows AM, Lanzino G, Rabinstein AA
(2015) Body mass index and aneurysmal subarachnoid hemor-
rhage: decreasing mortality with increasing body mass index.
World Neurosurg 84:1598–1604. https://doi.org/10.1016/j.wneu.
2015.07.019
19. Iliodromiti S, Celis-Morales CA, Lyall DM, Anderson J, Gray SR,
Mackay DF, Nelson SM, Welsh P, Pell JP, Gill JMR, Sattar N
(2018) The impact of confounding on the associations of different
adiposity measures with the incidence of cardiovascular disease: a
cohort study of 296 535 adults of white European descent. Eur
Heart J 39:1514–1520. https://doi.org/10.1093/eurheartj/ehy057
20. Kim BJ, Lee SH, Jung KH, Yu KH, Lee BC, Roh JK, For Korean
Stroke Registry i (2012) Dynamics of obesity paradox after stroke,
related to time from onset, age, and causes of death. Neurology 79:
856–863. https://doi.org/10.1212/WNL.0b013e318266fad1
21. Kim BJ, Lee SH, Ryu WS, Kim CK, Lee J, Yoon BW (2011)
Paradoxical longevity in obese patients with intracerebral hemor-
rhage. Neurology 76:567–573. https://doi.org/10.1212/WNL.
0b013e31820b7667
22. Kim Y, Kim CK, Jung S, Yoon BW, Lee SH (2015) Obesity-stroke
paradox and initial neurological severity. J Neurol Neurosurg
Psychiatry 86:743–747. https://doi.org/10.1136/jnnp-2014-308664
23. Knekt P, Reunanen A, Aho K, Heliovaara M, Rissanen A, Aromaa
A, Impivaara O (1991) Risk factors for subarachnoid hemorrhage in
a longitudinal population study. J Clin Epidemiol 44:933–939
24. KorjaM, Lehto H, Juvela S, Kaprio J (2016) Incidence of subarach-
noid hemorrhage is decreasing together with decreasing smoking
rates. Neurology 87:1118–1123. https://doi.org/10.1212/WNL.
0000000000003091
1562 Neurosurg Rev (2020) 43:1555–1563
25. Korja M, Silventoinen K, Laatikainen T, Jousilahti P, Salomaa V,
Kaprio J (2013) Cause-specific mortality of 1-year survivors of
subarachnoid hemorrhage. Neurology 80:481–486. https://doi.org/
10.1212/WNL.0b013e31827f0fb5
26. Kshettry VR, Rosenbaum BP, Seicean A, Kelly ML, Schiltz NK,
Weil RJ (2014) Incidence and risk factors associated with in-
hospital venous thromboembolism after aneurysmal subarachnoid
hemorrhage. J Clin Neurosci 21:282–286. https://doi.org/10.1016/j.
jocn.2013.07.003
27. Lindbohm JV, Kaprio J, Jousilahti P, Salomaa V, Korja M (2017)
Risk factors of sudden death from subarachnoid hemorrhage.
Stroke 48:2399–2404. https://doi.org/10.1161/STROKEAHA.117.
018118
28. NgM, Fleming T, RobinsonM, Thomson B, Graetz N,Margono C,
Mullany EC, Biryukov S, Abbafati C, Abera SF, Abraham JP, Abu-
RmeilehNM,Achoki T, AlBuhairan FS, AlemuZA, AlfonsoR,Ali
MK, Ali R, Guzman NA, Ammar W, Anwari P, Banerjee A,
Barquera S, Basu S, Bennett DA, Bhutta Z, Blore J, Cabral N,
Nonato IC, Chang JC, Chowdhury R, Courville KJ, Criqui MH,
Cundiff DK, Dabhadkar KC, Dandona L, Davis A, Dayama A,
Dharmaratne SD, Ding EL, Durrani AM, Esteghamati A,
Farzadfar F, Fay DF, Feigin VL, Flaxman A, Forouzanfar MH,
Goto A, Green MA, Gupta R, Hafezi-Nejad N, Hankey GJ,
Harewood HC, Havmoeller R, Hay S, Hernandez L, Husseini A,
Idrisov BT, Ikeda N, Islami F, Jahangir E, Jassal SK, Jee SH,
Jeffreys M, Jonas JB, Kabagambe EK, Khalifa SE, Kengne AP,
Khader YS, Khang YH, Kim D, Kimokoti RW, Kinge JM,
Kokubo Y, Kosen S, Kwan G, Lai T, Leinsalu M, Li Y, Liang X,
Liu S, Logroscino G, Lotufo PA, Lu Y, Ma J, Mainoo NK, Mensah
GA, Merriman TR, Mokdad AH, Moschandreas J, Naghavi M,
Naheed A, Nand D, Narayan KM, Nelson EL, Neuhouser ML,
Nisar MI, Ohkubo T, Oti SO, Pedroza A, Prabhakaran D, Roy N,
Sampson U, Seo H, Sepanlou SG, Shibuya K, Shiri R, Shiue I,
Singh GM, Singh JA, Skirbekk V, Stapelberg NJ, Sturua L, Sykes
BL, Tobias M, Tran BX, Trasande L, Toyoshima H, van de Vijver
S, Vasankari TJ, Veerman JL, Velasquez-Melendez G, Vlassov VV,
Vollset SE, Vos T, Wang C, Wang X, Weiderpass E, Werdecker A,
Wright JL, Yang YC, Yatsuya H, Yoon J, Yoon SJ, Zhao Y, Zhou
M, Zhu S, Lopez AD, Murray CJ, Gakidou E (2014) Global, re-
gional, and national prevalence of overweight and obesity in chil-
dren and adults during 1980-2013: a systematic analysis for the
Global Burden of Disease Study 2013. Lancet 384:766–781.
https://doi.org/10.1016/S0140-6736(14)60460-8
29. Oesch L, Tatlisumak T, Arnold M, Sarikaya H (2017) Obesity par-
adox in stroke - myth or reality? A systematic review. PLoSOne 12:
e0171334. https://doi.org/10.1371/journal.pone.0171334
30. Okorodudu DO, Jumean MF, Montori VM, Romero-Corral A,
Somers VK, Erwin PJ, Lopez-Jimenez F (2010) Diagnostic perfor-
mance of body mass index to identify obesity as defined by body
adiposity: a systematic review and meta-analysis. Int J Obes 34:
791–799. https://doi.org/10.1038/ijo.2010.5
31. Oliveros H, Villamor E (2008) Obesity and mortality in critically ill
adults: a systematic review and meta-analysis. Obesity (Silver
Spring) 16:515–521. https://doi.org/10.1038/oby.2007.102
32. Park YK, Yi HJ, Choi KS, Lee YJ, Chun HJ, Kwon SM (2018)
Predictive factors of fever after aneurysmal subarachnoid hemor-
rhage and its impact on delayed cerebral ischemia and clinical out-
comes. World Neurosurg. https://doi.org/10.1016/j.wneu.2018.03.
030
33. Platz J, Guresir E, Schuss P, Konczalla J, Seifert V, Vatter H (2013)
The impact of the body mass index on outcome after subarachnoid
hemorrhage: is there an obesity paradox in SAH? A retrospective
analysis. Neurosurgery 73:201–208. https://doi.org/10.1227/01.
neu.0000430322.17000.82
34. Rinaldo L, Hughes JD, Rabinstein AA, Lanzino G (2018) Effect of
body mass index on outcome after aneurysmal subarachnoid
hemorrhage treated with clipping versus coiling. J Neurosurg 129:
658–669. https://doi.org/10.3171/2017.4.JNS17557
35. Ryu WS, Lee SH, Kim CK, Kim BJ, Yoon BW (2011) Body mass
index, initial neurological severity and long-term mortality in ische-
mic stroke. Cerebrovasc Dis 32:170–176. https://doi.org/10.1159/
000328250
36. Sandvei MS, Mathiesen EB, Vatten LJ, Muller TB, Lindekleiv H,
Ingebrigtsen T, Njolstad I, Wilsgaard T, Lochen ML, Vik A,
Romundstad PR (2011) Incidence and mortality of aneurysmal sub-
arachnoid hemorrhage in two Norwegian cohorts, 1984-2007.
Neurology 77:1833–1839. https://doi.org/10.1212/WNL.
0b013e3182377de3
37. Schultheiss KE, Jang YG, Yanowitch RN, Tolentino J, Curry DJ,
Luders J, Asgarzadie-Gadim F, Macdonald RL (2009) Fat and neu-
rosurgery: does obesity affect outcome after intracranial surgery?
Neurosurgery 64:316–326; discussion 326-317. https://doi.org/10.
1227/01.NEU.0000336329.90648.17
38. Serrone JC, Wash EM, Hartings JA, Andaluz N, Zuccarello M
(2013) Venous thromboembolism in subarachnoid hemorrhage.
World Neurosurg 80:859–863. https://doi.org/10.1016/j.wneu.
2013.01.012
39. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew
M, Shekelle P, Stewart LA, Group P-P (2015) Preferred reporting
items for systematic review and meta-analysis protocols (PRISMA-
P) 2015: elaboration and explanation. BMJ 350:g7647. https://doi.
org/10.1136/bmj.g7647
40. Soros P, Hachinski V (2012) Cardiovascular and neurological
causes of sudden death after ischaemic stroke. Lancet Neurol 11:
179–188. https://doi.org/10.1016/S1474-4422(11)70291-5
41. Staplin N (2018) Confounding is not the only bias influencing
associations of adiposity with cardiovascular disease. Eur Heart J
39:1521–1522. https://doi.org/10.1093/eurheartj/ehy133
42. Strandberg TE, Strandberg AY, SalomaaVV, Pitkala KH, Tilvis RS,
Sirola J, Miettinen TA (2009) Explaining the obesity paradox: car-
diovascular risk, weight change, and mortality during long-term
follow-up in men. Eur Heart J 30:1720–1727. https://doi.org/10.
1093/eurheartj/ehp162
43. Suarez JI, Tarr RW, Selman WR (2006) Aneurysmal subarachnoid
hemorrhage. N Engl J Med 354:387–396. https://doi.org/10.1056/
NEJMra052732
44. Tawk RG, Grewal SS, Heckman MG, Navarro R, Ferguson JL,
Starke EL, Rawal B, Hanel R, Miller D, Wharen RE, Freeman
WD (2015) Influence of body mass index and age on functional
outcomes in patients with subarachnoid hemorrhage. Neurosurgery
76:136–141. https://doi.org/10.1227/NEU.0000000000000588
45. Wohlfahrt P, Lopez-Jimenez F, Krajcoviechova A, Jozifova M,
Mayer O, Vanek J, Filipovsky J, Llano EM, Cifkova R (2015)
The obesity paradox and survivors of ischemic stroke. J Stroke
Cerebrovasc Dis 24:1443–1450. https://doi.org/10.1016/j.
jstrokecerebrovasdis.2015.03.008
46. Yamada S, Koizumi A, Iso H, Wada Y, Watanabe Y, Date C,
Yamamoto A, Kikuchi S, Inaba Y, Toyoshima H, Kondo T,
Tamakoshi A, Japan Collaborative Cohort Study G (2003) Risk
factors for fatal subarachnoid hemorrhage: the Japan
Collaborative Cohort Study. Stroke 34:2781–2787. https://doi.org/
10.1161/01.STR.0000103857.13812.9A
47. Zhao L, Du W, Zhao X, Liu L, Wang C, Wang Y, Wang A, Liu G,
Wang Y, Xu Y (2014) Favorable functional recovery in overweight
ischemic stroke survivors: findings from the China National Stroke
Registry. J Stroke Cerebrovasc Dis 23:e201–e206. https://doi.org/
10.1016/j.jstrokecerebrovasdis.2013.10.002
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
1563Neurosurg Rev (2020) 43:1555–1563
